CA2408904A1 - Compositions and methods of using hiv vpr - Google Patents

Compositions and methods of using hiv vpr Download PDF

Info

Publication number
CA2408904A1
CA2408904A1 CA002408904A CA2408904A CA2408904A1 CA 2408904 A1 CA2408904 A1 CA 2408904A1 CA 002408904 A CA002408904 A CA 002408904A CA 2408904 A CA2408904 A CA 2408904A CA 2408904 A1 CA2408904 A1 CA 2408904A1
Authority
CA
Canada
Prior art keywords
vpr
nucleic acid
vpr protein
acid encoding
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002408904A
Other languages
English (en)
French (fr)
Inventor
Karuppiah Muthumani
David B. Weiner
Velpandi Ayyavoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2408904A1 publication Critical patent/CA2408904A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002408904A 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr Abandoned CA2408904A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19349500P 2000-03-31 2000-03-31
US60/193,495 2000-03-31
US23114100P 2000-09-08 2000-09-08
US60/231,141 2000-09-08
PCT/US2001/010028 WO2001074163A1 (en) 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr

Publications (1)

Publication Number Publication Date
CA2408904A1 true CA2408904A1 (en) 2001-10-11

Family

ID=26889047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002408904A Abandoned CA2408904A1 (en) 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr

Country Status (4)

Country Link
EP (1) EP1404705A1 (de)
AU (1) AU2001249576A1 (de)
CA (1) CA2408904A1 (de)
WO (1) WO2001074163A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254374A1 (de) * 2002-11-21 2004-06-03 Universitätsklinikum Hamburg-Eppendorf Körperschaft des Öffentlichen Rechts Adenovirale Vektoren zum Transfer von spezifischen Genen in Körperzellen
CA2772147C (en) 2009-09-16 2018-02-27 Basf Se Method for reducing nitrous oxide emission from soils
AU2022214429A1 (en) 2021-02-01 2023-09-14 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein

Also Published As

Publication number Publication date
EP1404705A4 (de) 2004-04-07
WO2001074163A1 (en) 2001-10-11
EP1404705A1 (de) 2004-04-07
AU2001249576A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
US5698202A (en) Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US7744896B1 (en) HIV-1 Tat compositions
Liu et al. T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice
JP4210798B2 (ja) 可溶性ｃｔｌａ４分子を用いる関心とする遺伝子の発現を延長する方法
JP2002515734A (ja) 遺伝子改変された樹状細胞により媒介される免疫刺激
US6692955B1 (en) HIV vaccine
US12060582B2 (en) Adenoviruses and methods for using adenoviruses
KR20120093941A (ko) 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
US20220106385A1 (en) Use of modified hiv-1 for generating fully human antibodies
US20110110892A1 (en) Vectors for delivering disease neutralizing agents
US20110123485A1 (en) Viral vectors for delivering vaccines for hiv and other infectious diseases
Norris et al. CD4+ T helper cells and the role they play in viral control
AU2003298554A1 (en) Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
US20050214258A1 (en) Vectors for delivering viral and oncogenic inhibitors
CA2408904A1 (en) Compositions and methods of using hiv vpr
US20040028651A1 (en) Composition and methods of using hiv vpr
JP2022504624A (ja) 拡大された抗原性スペクトルを有するエプスタイン・バーウイルス様粒子
FI105105B (fi) Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
AU2006203114B2 (en) Compositions and methods of using HIV Vpr
Hosoya et al. Comparison between Sendai virus and adenovirus vectors to transduce HIV‐1 genes into human dendritic cells
JP2011505837A (ja) アデノウイルス血清１４型に対するワクチン
US6953687B1 (en) Vectors for delivering viral and oncogenic inhibitors
Strack Transcriptional Targeting of Dendritic Cells as a New Therapeutic Vaccine against HIV-1
EP0879294A1 (de) Transduktion von menschlichen hämatopoiestischen stammzellen
Lang et al. Requirement for neutralizing antibodies to control bone marrow transplantation-associated persistent viral infection and to reduce immunopathology

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued